



R. 8-17-01

PATENT APPLICATION

Secdr
Box 50

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Tadahiko Kohno

Serial No.: 09/840,669

Group Art Unit No.:

Filed: April 23, 2001

Examiner:

For: APO-AI/AII PEPTIDE DERIVATIVES

Docket No.: A-690

TRANSMITTAL OF DECLARATION UNDER 37 CFR 1.51 (b)(2)
RESPONSE TO NOTICE TO FILE MISSING PARTS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is in response to a "Notice to file Missing Parts of Application" dated June 25, 2001 noting the absence of a declaration from the papers filed with the above-identified application.

Enclosed herewith are: 1) a copy of the Notice and 2) a Declaration under 37 CFR 1.51(b)(2) by the applicant(s) in this application.

Please charge Deposit Account No. 01-0519 in the amount of \$130.00 for the surcharge required by § 1.16(e). An original and one copy of this paper are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,

Timothy J. Gaul
Attorney for Applicant
Registration No.: 33,111
Phone: (805) 447-2688
Date: August 14, 2001

Please send all future correspondence to:
US Patent Operations/ TJG
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling
number:

EL360690133US


Date of
Deposit:

August 14, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum
Printed Name

Signature



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/840,669	04/23/2001	Tadahiko Kohno	A-690

CONFIRMATION NO. 4141

21069
AMGEN INCORPORATED
MAIL STOP 27-4-A
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320-1799

FORMALITIES LETTER



OC000000006223381

Date Mailed: 06/25/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600

06/29/2001 HNDGRI 00000115 010519 09040629
120.50 CH

- For Patent Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

HB

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Tadahiko Kohno

Serial No.: 09/840,669

Filed: April 23, 2001

For: APO-AI/AII PEPTIDE DERIVATIVES

Docket No.: A-690

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same. The sequence listing submitted herewith contains no new matter.

Respectfully submitted,

Timothy J. Gaul
Attorney for Applicants
Registration No.: 33,111
Phone: (805) 447-2688

Date: August 14, 2001

Please send all future correspondence to:
U.S. Patent Operations/ TJG
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling
number:

EL360690133US

Date of
Deposit:

August 14, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature